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Abstract
Predicting off-targets by computational methods is getting increasing importance in early drug discovery stages. We
herewith present a computational method based on binding site three-dimensional comparisons, which prompted us to
investigate the cross-reaction of protein kinase inhibitors with synapsin I, an ATP-binding protein regulating
neurotransmitter release in the synapse. Systematic pair-wise comparison of the staurosporine-binding site of the proto-
oncogene Pim-1 kinase with 6,412 druggable protein-ligand binding sites suggested that the ATP-binding site of synapsin I
may recognize the pan-kinase inhibitor staurosporine. Biochemical validation of this hypothesis was realized by competition
experiments of staurosporine with ATP-c
35S for binding to synapsin I. Staurosporine, as well as three other inhibitors of
protein kinases (cdk2, Pim-1 and casein kinase type 2), effectively bound to synapsin I with nanomolar affinities and
promoted synapsin-induced F-actin bundling. The selective Pim-1 kinase inhibitor quercetagetin was shown to be the most
potent synapsin I binder (IC50 =0.15 mM), in agreement with the predicted binding site similarities between synapsin I and
various protein kinases. Other protein kinase inhibitors (protein kinase A and chk1 inhibitor), kinase inhibitors
(diacylglycerolkinase inhibitor) and various other ATP-competitors (DNA topoisomerase II and HSP-90a inhibitors) did not
bind to synapsin I, as predicted from a lower similarity of their respective ATP-binding sites to that of synapsin I. The present
data suggest that the observed downregulation of neurotransmitter release by some but not all protein kinase inhibitors
may also be contributed by a direct binding to synapsin I and phosphorylation-independent perturbation of synapsin I
function. More generally, the data also demonstrate that cross-reactivity with various targets may be detected by systematic
pair-wise similarity measurement of ligand-annotated binding sites.
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Introduction
For long, drug designers had been focusing on a single
macromolecular target and a single or very few chemical series
[1]. The selectivity of preclinical candidates for the intended target
was only addressed relatively at a late stage by profiling the
compound against neighboring targets (e.g. receptor subtypes).
Therefore, a significant attrition rate in clinical trials in the last
decades [2] was due to the unexpected binding of drug candidates
to additional targets (off-targets [3] or anti-targets [4]) resulting in
dubious pharmacological activities, side effects and sometimes
adverse drug reactions [5]. Remarkable advances in structural
genomics [6,7] and diversity-oriented chemistry [8,9] have
changed these practices. On the biological side, the Protein Data
Bank [10] which stores publicly available three-dimensional (3-D)
structures of macromolecules currently stores over 65 000 entries.
Outstanding efforts of structural genomic consortia to complete
the structural proteome let us anticipate an acceptable coverage of
the UniProt database [11] in only 15 years [7]. On the chemical
side, about 27 million unique structures and 435 000 bioactivity
screens are available in the PubChem repository [12]. Mapping
pharmacological space in 2006 [13] resulted in more than 1 300
targets with significant affinities (,10 mm) for small molecular-
weight ligands. Global chemogenomic approaches [14] targeting
arrays of ligands (rows) and proteins (columns) to generate huge
two-dimensional binding matrices enlarge our vision of how
chemical and biological spaces match [15]. Experimental
chemogenomics is however expensive, time-consuming and
addresses only a restricted subset of chemical (a few thousand
ligands) and biological space (a few hundred targets). Combining
bio- and chemoinformatic structural approaches [13,16,17] to fill
chemogenomic matrices presents the noticeable advantage to
considerably extend space coverage and limit the number of
supporting experimental validations. Predicting missing data in
chemogenomic matrices can be operated on a column-by-column
(virtual screening of ligand libraries [18]) or on a row-by-row basis
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12214(virtual profiling of a ligand against an array of targets [19]). Two
main computational strategies are possible to profile a ligand
against a panel of putative targets. On one side, ligand-based
methods [9,20,21] aim at comparing chemical descriptors of
biologically-characterized ligands to transfer the target annotation
of similar molecules to the query ligand. To overcome structure-
activity cliffs [22] and gain statistical relevance, it is preferable to
compare sets of diverse ligands. Diverse descriptors and methods
have already been validated on existing data [23,24,25]. This
approach led to the discovery of several off-targets for known
drugs [20,21]. However, pure ligand-based methods have two
main drawbacks : (i) they are restricted by the incomplete coverage
of target space by known ligands and thus cannot be applied to
orphan proteins, (ii) the dogma stating that chemical similarity
implies biological similarity is only true in 30% of test cases [26].
On the other side, target-based approaches can also be used to
profile a ligand of interest. The most straightforward method is
docking a ligand to a collection of protein cavities [27,28,29,30].
This strategy led to the identification of novel targets for existing
ligands [5,31,32,33,34] or for a novel chemotype [35]. Molecular
docking is however notoriously hampered by the lack of reliable
binding free energy scoring functions [36] and the extreme
difficulty to automate the set-up of heterogeneous binding sites
[30]. Acknowledging that similar binding sites should recognize
similar ligands, a structure-based alternative to docking, is the 3-D
comparison of protein-ligand binding sites [37]. As for ligand-
based methods, structural descriptors of ligand-characterized
binding sites are used to transfer the ligand annotation of putative
targets to the query binding site. The method requires a proper
metric to compare binding sites in 3-D space and should be able to
detect global as well as local similarities among unrelated 3-D
structures. Despite the numerous methods described for measuring
3-D similarities between protein-ligand binding sites [37], there
are still very few reports of predictive target identifications by
systematic binding site comparisons (for a recent review see [38]).
We herewith present a predictive study supported by biochemical
and functional studies that successfully assigns an unexpected
target (synapsin I) to a series of therapeutically important bioactive
ligands (serine/threonine protein kinase inhibitors).
Results
The full computational protocol used to detect binding site
similarity between synapsin-I and some protein kinases is displayed
in Fig.1. Over 6,000 druggable protein-ligand binding sites from
the sc-PDB database [39] were screened (step a, Fig. 1) for their
similarity to the ATP-binding site of Pim-1 kinase (PDB entry 1yhs
with bound inhibitor staurosporine) using the previously described
SiteAlign algorithm [40]. From the list of similar binding sites (step
b), ATP-binding sites of protein kinases were removed due to their
obvious similarity (step c) and only proteins with at least 2 copies
(two different sc-PDB entries) were kept (step d). Synapsin-I is the
only hit (PDB entries 1aux and 1px2) and was used in a second
similarity screen (step e), yet as a reference, for finding among
ATP-binding sites which are similar. Among the list of possible hits
(step f), the sc-PDB entries were ranked by decreasing similarity to
1aux and corresponding proteins were ranked (step g) according to
a Receiver Operating Characteristic (ROC) classifying scheme
[40] from the statistically most similar (Pim-1 kinase) to the least
similar (panthothenate synthase).
Details of the multi-step protocol and the subsequent experi-
mental validations will be described from here on.
Figure 1. Computational protocol used to detect local similarities between ATP-binding sites in Pim-1 kinase and Synapsin I. a) The
ATP-binding site in Pim-1 kinase (occupied by the ligand staurosporine) is compared with SiteAlign [41] (step a) to 6,415 binding sites stored in the
sc-PDB database . Among top scoring entries (step b), synapsin I is the only protein not belonging to the protein kinase target family (step c) and
present in numerous copies (step d). A systematic SiteAlign comparison (e) of the ATP-binding site in synapsin-I with 978 other ATP-binding sites
suggest that some but not all ATP-binding sites of protein kinases (steps f, g) are similar to that of synapsin I.
doi:10.1371/journal.pone.0012214.g001
Binding Sites Comparison
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strikingly similar features
In benchmarking our 3-D binding site comparison algorithm
(SiteAlign) [41], we have previously compared ATP-binding sites
of protein kinases with other druggable protein-ligand cavities
from the sc-PDB database [39]. The ATP-binding site of synapsin
I was predicted to be similar to that of a pan-kinase inhibitor
(staurosporine) [42] with the proto-oncogene Pim-1 serine/
threonine protein kinase (Fig. 2A).
Protein kinases catalyze the reversible phosphorylation of
proteins and constitute a family of macromoleuclar targets of
utmost interest for their central implication in signal transduction
pathways [43]. Thanks to existing X-ray structures [44], various
inhibitors competing with the ATP substrate and exhibiting
different selectivity profiles [42] towards the 518 human protein
kinases have been designed, and some of them have reached the
market as anti-cancer drugs [45].
Synapsin I belongs to an evolutionary conserved family of
neuron-specific, synaptic vesicle-associated phosphoproteins in-
volved in the regulation of neurotransmitter release, synaptic
plasticity and synaptogenesis [46,47,48]. Synapsin isoforms are
composed of a mosaic of shared and individual domains, among
which the amino-terminal domain A and the large central domain
C are the most conserved across isoforms and species [49,50]. The
crystal structure of the recombinant C domain [51] or ABC
domains [52] of synapsin I revealed a high similarity to proteins of
the ATP-grasp superfamily, notably glutathione synthase, and the
presence of tightly associated dimers that can associate in a
tetramer. Indeed, in vitro studies showed that ATP binds to all
synapsins and that synapsins form homo- and hetero-oligomers
[53,54,55]. The binding of ATP affects the oligomerization state of
the synapsin ABC domains [52] and the interaction of synapsin I
with the immunophilin cyclophillin B [56]. Moreover, synapsin I is
a major presynaptic substrate of distinct protein kinases including
PKA, CaM kinases I/II/IV, MAPK/Erk, cdk5, PAK and Src
[46,57,58,59,60] that regulates synaptic vesicle trafficking, synap-
tic plasticity and neuronal development in a phosphorylation-
dependent fashion [61,62,63,64,65,66,67,68]. Based on the
structural similarity between the crystal structure of the synapsin
Figure 2. Similarity of the ATP-binding sites of Pim-1 kinase and of synapsin I. A. SiteAlign [41] virtual screening of 6 415 sc-PDB binding
sites to the staurosporine binding site of human Pim-1 kinase (1yhs). Entries exhibiting similar binding site properties (d2 ,0.20) are ranked by
decreasing d2 distance to the query. ATP-binding sites of protein kinases are displayed by dark circles, other binding sites by red stars. Two ATP-
binding sites of synapsin I are labeled by their Protein Data Bank entry name (1aux, 1px2). B. 3-D SiteAlign alignment of human Pim-1 (1yhs, blue
ribbons) bound to staurosporine (cyan sticks) and of bovine synapsin I (1aux, orange ribbons) bound to adenosine 59-diphosphate
monothiophosphate (yellow sticks). Nitrogen, oxygen and sulfur atoms of bound ligands are colored in blue, red and orange, respectively. C. 11
matching residues between the ATP-binding sites of Pim-1 (1yhs, cyan sticks) and synapsin I (yellow sticks). Residues are labeled according to the PDB
residue numbering at their Ca atom. D. Putative docking pose of staurosporine (yellow sticks) to the bovine synapsin I X-ray structure (1aux, cyan
ribbons). Protein-ligand hydrogen bonds are displayed by green dots.
doi:10.1371/journal.pone.0012214.g002
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binding site has been mapped in domain C [50,51] and found to
bind ATP with nanomolar affinity in a Ca
2+-dependent manner
[54]. Although very few data exist in the literature, it has been
reported that a domain C peptide corresponding to a sequence
between the ATP binding site and the Ca
2+-binding site speci-
fically inhibits the binding of synapsin I to F-actin [69]. ATP
binding to synapsin I facilitates the transition from dimer to
tetramer [52] and inhibits cyclophilin B binding [56].
We showed in the first series of computations (Fig. 2A) that
ATP-binding sites of protein kinases do not resemble neither ATP-
binding sites of other kinases nor other ATP-binding cavities
[41,70]. It is therefore not surprising that 123 out of the 134
binding sites (92%) scored above an acceptable similarity threshold
(SiteAlign d2 score ,0.2)[41] are annotated as ATP-binding sites
in protein kinases (Fig. 2A, Supplementary Table S1). Out of
the 11 outliers, two entries (PDB entries 1aux and 1px2) drew our
attention since they both describe the ATP-binding site of synapsin
I. Despite a low homology (21%) between human Pim-1 (1yhs) and
bovine synapsin I (1aux) amino acid sequences, the proposed 3-D
alignment between both binding sites reveal remarkable shared
features. Although both proteins adopt distinct 3-D folds, their
bound ligands (staurosporine in Pim-1, ATP-cS in synapsin I) in
the cognate X-ray structures occupy a similar orientation in their
respective binding sites (Fig. 2B). Out of the 32 and 24 cavity-
lining residues in 1yhs and 1aux, respectively, 11 amino acids
matched in both their chemical properties and 3-D spatial
coordinates (Fig. 2C). 6 pairs of short side-chain aliphatic
residues, one pair of lysine residues, two pairs of negatively-
charged amino acids, one pair of glycine and one pair of serine
residues are absolutely conserved in both binding sites (Fig. 2C).
To be sure that non-conserved residues in the synapsin I site would
not impair staurosporine recognition, we attempted preliminary
docking experiments of the latter ligand to the 1aux structure.
Only the floppy Lys67 side chain which points inward the ATP-cS
binding site was rendered flexible during docking to putatively
enlarge the cavity. Docking staurosporine in synapsin I with the
GOLD software (see structure in Fig. 3A) provided a single set of
similar binding poses with mostly hydrophobic intermolecular
contacts and a bidentate hydrogen bond to main chain atoms of a
hinge region (Pro
306, Ile
308; see top-ranked pose Fig. 2D).
Staurosporine binds to synapsin I and enhances
synapsin- F-actin interactions
The in silico predicted interaction between staurosporine and
synapsin I was tested by in vitro experiments aimed at analyzing the
ability of staurosporine to competitively inhibit ATPc
35S binding
to synapsin I [53,54] or to affect the interactions of synapsin I with
actin which occur through a major binding site in domain C
[71,72,73]. When purified bovine synapsin I was incubated with
ATPc
35S in the absence or presence of increasing concentrations
of either staurosporine or cold ATP (Fig. 3A), both ligands were
Figure 3. Staurosporine binds to synapsin I and affects synapsin I-dependent F-actin bundling. A. Upper panel: Chemical structure of
staurosporine. Lower panel : Inhibition of ATP-c
35S (0.2 mM) binding to purified bovine synapsin I (0.5 mM) by increasing concentrations of either cold
ATP (open triangles) or staurosporine (filled circle). The amount of ATP-c
35S bound in the presence of the inhibitors is expressed in percent of the
binding under control conditions (absence of either inhibitor). Points in the plot are means 6 sem from 5 independent experiments. Inhibition curves
were fitted using a 3-parameter sygmoidal dose-response function yielding IC50 and lower plateau values (see Fig. 6). B. The F-actin bundling activity
of synapsin I (final concentrations : synapsin I, 0.5 mM; F-actin, 5 mM) in the absence or presence of the indicated concentration of staurosporine (1–
20 mM) was evaluated by using the low speed sedimentation assay. The actin recovery in the pellet was evaluated by densitometric analysis of the
actin bands from Coomassie-stained gels of the solubilized pellets. A representative experiment is shown in the upper panel (staurosporine
concentrations are shown in mM). The percent increases in actin bundling observed in the presence of increasing concentrations of staurosporine,
with respect to the samples containing F-actin and synapsin I only, is shown in the lower panel as means 6 sem from 5 independent experiments.
Statistical analysis was carried out by one-way Anova followed by the post-hoc Dunnett’s multiple comparison test (*, p,0.05 ; **, p,0.01).
doi:10.1371/journal.pone.0012214.g003
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35S in a concentration-dependent fashion
(IC50 0.0760.01 mM and maximal inhibition 95.862.2% for
ATP; IC50 0.3160.09 mM and maximal inhibition 84.361.2% for
staurosporine), indicating that staurosporine bound synapsin I at
the ATP binding site.
Since the Synapsin I ATP binding pocket is localized in the
synapsin domain primarily involved in actin binding [69,72], we
investigated whether staurosporine binding is able to affect the
synapsin I-actin interaction. To this aim, we evaluated the F-actin
binding/bundling activity under conditions of ATP binding to
synapsin I in the presence of increasing concentrations of
staurosporine ranging from to 1 to 20 mM. The amount of F-
actin/synapsin I bundles recovered by low speed sedimentation
was increased by staurosporine by approximately 30% at 5 mM
(Fig. 3B), indicating that binding of the kinase inhibitor to the ATP
binding site of synapsin I modifies its molecular interactions with
the F-actin-based cytoskeleton.
Synapsin I is closer to Pim-1 than to other protein kinases
Staurosporine is a pan-kinase inhibitor exhibiting not only
nanomolar affinities to Pim-1 but also to a wide array of protein
kinases [42]. To ascertain whether the ATP-binding site of synapsin
I is equally close to all known ATP-binding sites or specifically
related to Pim-1, we computed with SiteAlign [41] the distance
between the ATP-binding site of bovine synapsin I (1aux) and 978
ATP-binding sites from the Protein Data Bank. The 978 ATP-
binding binding sites were extracted from the sc-PDB database [39]
and feature a total of 433 unique proteins among which 110 are
protein kinases. 113 entries describing 46 different protein kinases
present a binding site distance below 0.20, the previously-
determined computed threshold for discriminating similar from
dissimilar binding sites [41]. This result suggests that the ATP site of
synapsin I is similar to that of many other protein kinases. When
looking at the top 25 ranked entries (Table 1), Pim-1 binding sites
to various ATP-competitive inhibitors are the most numerous (8
times), but other serine/threonine protein kinases (e.g. casein kinase
II) also share strong binding site similarities with the ATP site of
synapsin I. A statistical analysis of binding site distances (SiteAlign
d2 distance) to that of synapsin I was undertaken by computing, for
each single protein present at least in 5 copies in the sc-PDB, the
area under the ROC curve [40] in a simple binary classification
system (similar, dissimilar) is calculated. Briefly, each of the 978
ATP-binding sites are ranked by decreasing distance to that of
synapsin I and the rank distribution of every binding site sharing the
same protein name (true positives are presumed similar to the
reference) are compared to the ranks of all other active sites (true
negatives are presumed dissimilar to the reference, see full results in
Supplementary Table S2).
Table 1. The 25 ATP-binding sites of protein kinases closest to that of bovine synapsin I (PDB entry 1aux).
PDB
a d2
b Name HET
c
2oxd 0.1008 Casein kinase II subunit alpha K32
2oxx 0.1038 Casein kinase II subunit alpha K22
1yi3 0.1056 Proto-oncogene serine/threonine-protein kinase Pim-1 LY2
1tqm 0.1083 RIO-type serine/threonine-protein kinase Rio2 ANP
3cy3 0.1176 Proto-oncogene serine/threonine-protein kinase Pim-1 JN5
3bgz 0.1199 Proto-oncogene serine/threonine-protein kinase Pim-1 VX3
3cy2 0.1233 Proto-oncogene serine/threonine-protein kinase Pim-1 MB9
2bik 0.1327 Proto-oncogene serine/threonine-protein kinase Pim-1 BI1
2c1a 0.1339 Protein kinase A I5S
1xr1 0.1350 Proto-oncogene serine/threonine-protein kinase Pim-1 ANP
1bl6 0.1368 Mitogen-activated protein kinase 14 SB6
1q8u 0.1385 cAMP-dependent protein kinase catalytic subunit alpha H52
3bi6 0.1388 Wee1-like protein kinase 396
3biz 0.1395 Wee1-like protein kinase 61E
2i0e 0.1400 Protein kinase C beta type PDS
1cm8 0.1405 Mitogen-activated protein kinase 12 ANP
2uzv 0.1423 cAMP-dependent protein kinase catalytic subunit alpha SS5
1yi4 0.1456 Proto-oncogene serine/threonine-protein kinase Pim-1 ADN
2hen 0.1467 Ephrin type-B receptor 2 ADP
2rkp 0.1474 Casein kinase II subunit alpha RFZ
2ojg 0.1481 Mitogen-activated protein kinase 1 19A
2z7s 0.1481 Ribosomal protein S6 kinase alpha-1 P01
2csn 0.1482 Casein kinase I homolog 1 CKI
1yhs 0.1483 Proto-oncogene serine/threonine-protein kinase Pim-1 STU
1mu 0.1508 Serine/threonine-protein kinase 6 ADN
aPDB entry [10].
bSiteAlign [41] distance measuring the local similarity to the query binding site (1aux).
cLigand Chemical Component identifier in the cognate PDB complex (http://ligand-expo.rcsb.org/ld-search.html).
doi:10.1371/journal.pone.0012214.t001
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AUC =0.85) to significant (e.g. casein kinase II or CKII, cyclin-
dependent kinase 2 or CDK2; AUC .0.65) to random (protein
kinase A or PKA, Heat shock protein-90a or HSP-90a; AUC
<0.50) and to even worse than random (Checkpoint kinase 1 or
CHK1, DNA topoisomerase II, Diacylglycerolkinase or DGK;
AUC ,0.50; Fig. 4). We therefore predicted that inhibitors of
protein active sites presenting a high ROC AUC value (Pim-1
kinase, CDK2, CKII) should cross-react with synapsin I whereas
inhibitor of other proteins presenting a close-to-random of even
lower AUC value (PKA, HSP-90a, CHK1, DNA topoisomerase
II, DGK) should not. One high-affinity inhibitor (Fig. 5) of each
of these 8 representative targets was purchased and tested for in
vitro binding to bovine synapsin I. It is important to point out that
these commercially available inhibitors and/or very close analogs
have all been co-crystallized in the ATP-binding site of their
respective target.
In qualitative agreement with the predictions, the Pim-1 kinase
inhibitor quercetagetin was the most potent binder to synapsin I
(IC500.1560.08 mM; maximal inhibition of 88.364.9%;
Fig. 6A,B). (R)-roscovitin and compound 70159800251 still
compete with ATP for binding to bovine synapsin I but with a
higher IC50 value (1.0 and 0.5 mM, respectively) and a lower level
of maximal inhibition (ca. 70%, Fig. 6B). Among other inhibitors
tested here, other protein kinase inhibitors (PKA and CHK1
inhibitors) did not show any significant binding to synapsin I
(Fig. 6A).
Discussion
Comparing at high-throughput 3-D features of protein cavities
is likely to play an increasing role to guide the functional
annotation of novel genomic structures as well as predicting target-
based selectivity profiles for pharmacological ligands. Despite
several sequence and fold-independent computational methods
have been proposed to detect remote binding site similarities
among unrelated proteins [37], there are very few in silico studies
guided by binding site comparisons that successfully predicted
either the function of a protein from its 3-D structure or assigned a
novel macromolecular target to an existing ligand. The SOIPPA
method [74] was successfully used to predict remote binding site
similarities between the binding site of selective estrogen receptor
modulators (SERMs) at the ERa receptor and the Sarcoplasmic
Reticulum Ca2 ion channel ATPase protein (SERCA) transmem-
brane domain [75], thus explaining known side effects of SERMs.
Likewise, the NAD binding site of the Rossmann fold and the S-
adenosyl-methionine (SAM)-binding site of SAM-methyltransfer-
ases were found to be similar and consequently permitted the
prediction of the cross-reactivity of catechol-O-methyltransferase
(COMT) inhibitors (entacapone, tolcapone) with the M.tuberculosis
enoyl-acyl carrier protein reductase (InhA) [76]. The same
approach predicted two unexpected targets for a known inhibitor
of Trypasonoma brucei RNA editing ligase [77]. Last, the
PocketPicker algorithm [78] was used to detect a cavity on the
surface of a APOBEC3A structure, a protein which is able to
inactivate retroviral genomes. Encoding the pocket as correlation
vectors enabled the comparison of a set of 1300 ligand-binding
sites from the PDBBind dataset [79]. Among top scoring entries
were only nucleic acid-binding pockets [80]. Point mutation of the
cavity-lining residues effectively led to mutants with a reduced
antiviral activity. The pocket was shown to recognize the small
5.8S RNA [80] as a preliminary step to inactivate retroviral
particles.
The main reason for the paucity of predictive reports is that
many 3-D site comparison tools are extremely sensitive to atomic
coordinates and thus better suited to detect global than local
similarities [81]. In this context, a true advantage of the SiteAlign
algorithm, used in the current study to detect local similarity
between ATP-binding sites of Pim-1 kinase and synapsin I, is that
cavity descriptors are assigned to Ca carbon atoms thus rendering
the method fuzzy enough to be relatively insensitive to variations
in 3-D coordinates (e.g. rotameric state and orientation of a side
chain). A good illustration of this feature is exemplified by the
matching of Pim-1 to synapsin I binding sites (Fig. 2C) which
clearly shows a good fit of several pairs of residues (Lys67 vs.
Lys269, Glu121 vs. Glu305) with significantly different side chain
orientations. Recently-described alignment-independent binding
site comparison methods (PocketMatch [82], FuzCav [70])
focusing on protein C-a atoms also found a significant similarity
score between 1yhs and 1aux active sites (PocketMatch PMscore
=50.79; FuzCav score =0.160). Conversely, two state-of-the-art
full atom-matching methods (SitesBase [83], SiteEngine [84])
failed in finding the same binding sites similar (SiteEngine Match
score =18.71; no output for SitesBase). SiteEngine notably fails to
fit the pair of glutamic acid residues (Glu121 vs. Glu305, recall
Fig. 2C) diverging in the orientation of their side chains. A
detailed binding site representation at the atomic level is therefore
detrimental to the detection of remote similarity between synapsin
I and Pim-1 kinase.
The herein predicted remote similarity between ATP-binding
sites of Pim-1 kinase and synapsin I could be experimentally
validated by an in vitro competition assay. The affinity of
staurosporine, a pan-kinase inhibitor, to bovine synapsin I is
about 0.3 mM( Fig. 3). It is thus comparable to that observed for
most serine/threonine protein kinases [42]. The polypharmaco-
logical profile [85] of staurosporine may be attributed to its
lipophilicity and the tendency to recognize apolar surface patches.
Figure 4. Similarity of ATP-binding proteins to bovine synapsin
I. ATP-binding proteins present in at least 5 copies in the sc-PDB
dataset (n=43) are ranked by decreasing ROC score (area under the
ROC curve), iteratively computed for each protein from the SiteAlign
[41] alignment (d2 score) to the ATP-binding site of bovine synapsin I
(PDB entry 1aux). Protein kinases are underlined. PIM 1, Proto-oncogene
serine/threonine-protein kinase Pim-1; CK II, Casein kinase II subunit
alpha; CDK2, Cell division protein kinase 2 (cyclin-dependent kinase 2) ;
PKA, cAMP-dependent protein kinase catalytic subunit alpha (Protein
kinase A); HSP-90a, Heat shock protein HSP 90-alpha; CHK1, Serine/
threonine-protein kinase Chk1; DTI II, DNA topoisomerase II, DGK,
Diacylglycerolkinase).
doi:10.1371/journal.pone.0012214.g004
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remarkably reminiscent from that seen in protein kinases with a
bidentate hydrogen bond to main chain atoms of a hinge region
accompanying apolar interactions (Fig. 2D). Binding to synapsin I
could be verified for other inhibitors (roscovitin, quercetagetin,
70159800251) targeting different protein kinases (cyclin-depen-
dant kinases, Pim-1, casein kinase II), still with submicromolar
affinities (Fig. 5). One might argue that a remote similarity among
ATP-binding sites is trivial and that the herein presented data are
not surprising. Interestingly, the ATP-binding site of synapsin I
was predicted to be much more distant from that of other serine/
threonine protein kinases (e.g. Chk1, PkA; Fig. 4) and this
assumption could be verified in vitro by testing inhibitors of the
latter proteins for binding to synapsin I (Fig. 6). Other ATP-
competitors binding to a kinase (DGK) or two other targets (DNA
topoisomerase II, HSP-90a) did not either bind to synapsin I
(Fig. 6A). Our data therefore pinpoints a binding site similarity
between synapsin I and some serine/threonine protein kinases but
not all of them.
Off-targets for protein kinase inhibitors outside the protein
kinome (e.g. glycogen phosphorylase, malate dehydrogenase,
HSP-90b) have already been discovered by proteomics
[86,87,88] although no inhibition constants have been reported.
Notably, roscovitin binds to pyridoxal kinase at the pyridoxal but
not the ATP-binding site [32]. We herewith supplement the list of
off-targets for four protein kinase inhibitors with synapsin I.
Binding affinities in an ATP-c
35S competition assay are remark-
ably high (submicromolar) and comparable to those seen for
protein kinases.
Since some protein kinase inhibitors tested here actively and
directly compete for the binding of ATP to synapsin I and modify
the interactions of synapsin I with the actin-based cytoskeleton, it
is tempting to speculate that at least some of the effects of protein
kinase inhibitors on neurotransmitter release and presynaptic
function are attributable to a direct binding to synapsin I and
reveal new potential targets for the action of protein kinase
inhibitors on synaptic transmission and plasticity.
Materials and Methods
Virtual screening of sc-PDB binding sites
Protein-ligand binding sites were retrieved from the 2006
release of the sc-PDB (http://bioinfo-pharma.u-strasbg.fr/scPDB),
a database of 6 415 druggable protein-ligand binding sites [39]
from the Protein Data Bank. A binding site is described by any
amino acid for which at least one heavy atom is closer than 4.5 A ˚
from any heavy atom of the bound pharmacological ligand. The
full sc-PDB dataset was screened for similarity to the staurospor-
Figure 5. Chemical structures of compounds tested for binding to bovine synapsin I. (R)-Roscovitin (CDK2 inhibitor), Quercetagetin (Pim-1
kinase inhibitor), 7015980251 (Casein kinase II inhibitor), H-89 (protein kinase A inhibitor), 4072–2730 (Protein kinase Chk1 inhibitor), R59022
(diacylglycerolkinase inhibitor), Novobiocin (DNA topoisomerase II inhibitor), and CCT018159 (HSP-90 alpha inhibitor).
doi:10.1371/journal.pone.0012214.g005
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standard settings of the SiteAlign v4.0 program. Algorithmic
details of SiteAlign have been described elsewhere [41]. Briefly,
eight topological and physicochemical attributes are projected
from the Ca-atom of cavity-lining residues to an 80 triangle-
discretized polyhedron placed at the center of the binding site, thus
defining a cavity fingerprint of 640 integers. 3-D alignment is
performed by moving the sphere within the target binding site
while keeping the query sphere fixed. After each move, the
distance of the newly described cavity descriptor is compared to
that of the query, the best alignment having the minimal distance
between both cavity fingerprints. Two distances are used in
SiteAlign. The d1 distance is suited to measure global similarities
and is a sum of normalized distances between the 8 descriptors on
all indexed triangles with non-null values for either the query or
the target. Previous benchmarking studies suggest that a d1
distance of 0.60 is a good threshold for discriminating similar from
dissimilar binding sites [41]. The d2 distance is suited to measure
local similarities and is a sum of normalized distances between the
8 descriptors on all indexed triangles with non-null values for both
the query and the target. Previous benchmarking studies suggest
that a d2 distance of 0.20 is a good threshold for discriminating
similar from dissimilar binding sites. In the current screen, sc-PDB
entries were ranked by increasing d2 distance to the 1hys query.
To avoid false positives [41], the d2 distance was post-processed
and set to 1.0 if the corresponding d1 distance is higher than 0.60.
Screening for binding site similarity to the ATP-binding site of
bovine synapsin (PDB entry 1aux) was done as described above.
The dataset of 978 ATP-binding sites was selected from the
current sc-PDB database as previously described [41,70]. SiteAlign
screen was performed using standard settings and entries were
ranked by increasing d2 distance with the same post-processing as
previously described (d2=1 if d1 .0.6). A ROC score (area under
the ROC curve) is computed from the distance table with an in-
house Pipeline Pilot workflow [89] for each occurrence of a
protein name represented by at least 5 entries in the dataset
(n=43). The higher the ROC score for a particular protein, the
more similar its protein-ligand binding sites to that of the synapsin
Figure 6. Binding of distinct ATP-competitors to the ATP-binding site of bovine synapsin I. A. Inhibition curves of ATP-c
35S (0.2 mM)
binding to purified bovine synapsin I (0.5 mM) by increasing concentrations of either cold ATP (closed triangles), quercetagetin (open circles),
roscovitin (closed circles), H-89 (closed diamond), 7015980251 (open diamond), R59022 (open hexagon), CCT018159 (closed hexagon), 4072–2730
(open square) and novobiocin (closed square). The amount of ATP-c
35S bound in the presence of the inhibitors is expressed in percent of the binding
under control conditions (absence of either inhibitor). Points in the plot are means 6 sem from 5 independent experiments. Inhibition curves were
fitted using a 3-parameter sigmoidal dose-response function. B. IC50 (upper panel) and lower plateau (lower panel) values were calculated from
individual curve fittings and are shown as means 6 sem from 5 independent experiments. The values of H-89 (IC50 .30 mM) and the inactive
compounds (R59022, CCT018159, 4072–2730 and novobiocin) are not reported. Statistical analysis was carried out by one-way Anova followed by the
post-hoc Bonferroni’s multiple comparison test (* p,0.05, ** p,0.01 vs ATP ; u p,0.05, uu p,0.01 vs roscovitin). CKII-I, 70159800251; QUERCE
Quercetagetin; ROSCO, (R)-Roscovitin; STAURO, Staurosporine.
doi:10.1371/journal.pone.0012214.g006
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d2 scores for a particular protein.
Automated docking of staurosporine to bovine
synapsin I
3-D atomic coordinates of staurosporine were obtained by
Corina v3.5[90] from a 2-D Marvin sketch [91]. Hydrogen atoms
were added using standard topological rules in Sybyl v.8.0 [92]
and coordinates were saved in mol2 format. Standard settings of
the Gold v4.1 program [93] were used to dock staurosporine to the
ATP-binding site of bovine synapsin (PDB entry 1aux) whose
coordinates were retrieved from the sc-PDB databank [30]. The
cavity was defined as any protein atom present in a 10 A ˚-radius
sphere centered on the center of mass of the sc-PDB binding site.
The side chain of Lys67 was considered flexible during the docking
by explicit definition of 27 rotameric states from the standard Gold
rotamer library. Poses were scored with the Goldscore fitness
function.
Comparison of bovine synapsin I and human Pim-1 ATP-
binding sites with other binding site matching methods
ATP-binding sites of 1aux (bovine synapsin I) and 1yhs (human
Pim-1 kinase) were retrieved from the sc-PDB website (http://
bioinfo-pharma.u-strasbg.fr/scPDB) and compared with the in-
house FuzCav algorithm with default parameters [70]. Web
interfaces to SitesBase [83] (http://www.modelling.leeds.ac.uk/
sb/), SiteEngine [84] (http://bioinfo3d.cs.tau.ac.il/SiteEngine/)
and PocketMatch [82] (http://proline.physics.iisc.ernet.in/
pocketmatch/) were used to compare the same entries. Active
site detection was here achieved by specifying the chemical
component HET code of the co-crystallized ligands (SAP for 1uax,
STU for 1yhs).
ATP-c
35S binding assays
Synapsin I was purified from bovine brain [71] and stored in
liquid nitrogen in 200 mM NaCl, 25 mM TrisCl, pH 7.4.
Synapsin I (500 nM) was incubated with 200 nM ATP-c
35S
(Perkin Elmer, Waltham, MA) in 50 mM HEPES-NaOH pH 7.4,
25 mM NaCl, 0.5 mM CaCl2 and 2 mM MgCl2 for 1 h at room
temperature in the absence or presence of increasing concentra-
tions (0.1–30 mM) of either cold ATP, staurosporine (Sigma,
Milan, Italy), (R)-roscovitin (Caiman, Ann Arbor, MI), querceta-
getin (Calbiochem, San Diego, CA), 70159800251 (Otava, kiev,
Ukraine), H-89 (LC Laboratories, Woburn, MA), 4072–7730
(ChemDiv, San Diego, CA), R59022 and novobiocin (MP
Biochemicals, Illkirch, France) and last CCT018059 (SPI-Bio,
Montigny Le Bretonneux, France). ATP-c
35S binding was
quantified as previously described [94]. Briefly, aliquots of the
samples were spotted onto squares of phosphocellulose paper
(Upstate/Millipore, Billerica, MA). The paper squares were
extensively washed with deionized water for 30 min, air-dried
and analyzed for radioactivity by using the Perkin Elmer Cyclone
Plus Phosphor Imager. After subtraction of the background values
(samples with no synapsin I), data from individual competition
curveswere fittedwitha sigmoidaldose-responsefunction(f=min+
(max–min)/(1+10‘((logEC50-x)*Hillslope)) using the Sigmaplot 8.0
software (SPSS Inc., Chicago, IL) to yield IC50 and maximal
inhibition values. Data in the plots are the means 6 sem of at least 5
independent experiments.
Actin Bundling Assays
Actin was purified from acetone powder of rabbit skeletal
muscles [95,96] and stored in liquid nitrogen in in 2 mM Tris
pH 8, 0.2 mM ATP, 0,2 mM CaCl2, 0.125 mM b-mercaptoeth-
anol and 0.005% NaN3 (G-buffer). Before the experiments, both
G-actin and synapsin I were prespun for 1 h at 4uC at 300,0006g
to remove large aggregates. G-actin was polymerized at room
temperature for 1 h in the presence of 100 mM KCl, 1.2 mM
MgCl2. Synapsin I (final concentration, 0.5 mM) was preincubated
with increasing concentrations (1–20 mM) of staurosporine for 1 h
at room temperature in 200 mM NaCl, 25 mM TrisCl pH 7.4.
Actin bundling was assessed by incubating the synapsin/stauro-
sporine samples with F-actin (final concentration, 5 mM) under
polymerization conditions (100 mM KCl, 1.2 mM MgCl2 in G-
buffer) for 1.5 h at room temperature followed by low-speed
centrifugation (10,0006 g for 15 min) to separate actin bundles
(Bahler & Greengard, 1987). Pellets were solubilized in sample
buffer [97] and analyzed by sodium dodecylsulfate polyacrylamide
gel electrophoresis (SDS-PAGE) using 10% acrylamide in the
resolving gel. Gels were fixed, stained with Coomassie Blue and
destained. Densitometric analysis of the actin bands was carried
out by using the ImageQuant system (GE Healthcare) followed by
densitometric analysis of the fluorograms and by data interpola-
tion into a standard curve of purified G-actin run in parallel with
the unknown samples.
Supporting Information
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Found at: doi:10.1371/journal.pone.0012214.s001 (0.04 MB
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